Radiopharm Theranostics

Radiopharm Theranostics is a clinical-stage company developing radiopharmaceuticals for the diagnosis and treatment of cancer, using nanobody, antibody, small-molecule and peptide platforms directed at targets other than PSMA, FAP and SSTR2. It has a joint venture with MD Anderson Cancer Center and is listed in Australia and on Nasdaq. On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in Nuclide: NCT07189871 (phase 1/2, 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Me...), NCT07259213 (phase 1/2, A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC) and NCT06777433 (phase 2, Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.